<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409591</url>
  </required_header>
  <id_info>
    <org_study_id>PHPT-5 First Phase</org_study_id>
    <secondary_id>R01HD052461</secondary_id>
    <secondary_id>R01HD056953</secondary_id>
    <nct_id>NCT00409591</nct_id>
  </id_info>
  <brief_title>Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand</brief_title>
  <acronym>PHPT-5</acronym>
  <official_title>Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of two doses of nevirapine (NVP) given
      only to the infants or lopinavir/ritonavir (LPV/r) from 28 weeks gestation with single dose
      (SD) NVP given to the mothers plus two doses to the infants, in addition to zidovudine (ZDV)
      prophylaxis (from 28 weeks' gestation and for one week of ZDV in neonates) for the prevention
      of mother-to-child transmission of HIV-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, placebo-controlled, double blind, clinical trial where non immunocompromised
      women receiving the ZDV prophylaxis regimen from 28 weeks gestation, as recommended in
      Thailand, will be randomized to one of two arms:

      Arm 1: NVP-NVP:

        -  In women, one NVP 200 mg tablet at onset of labor+;

        -  In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus
           a second dose between 48 and 72 hours+++

      Arm 2: PL-NVP:

        -  In women, one placebo tablet at onset of labor++;

        -  In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus
           a second dose between 48 and 72 hours+++

      Arm 3: LPV/r:

        -  In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery

             -  women in Arm 1 will also receive 7-day ZDV 300mg bid plus 3TC 150mg bid from
                delivery. ++women in Arm 2 will also receive 7-day (ZDV+3TC) Placebo from delivery.
                +++If the new born weight less than 2500 g, nevirapine will be administered 2 mg./1
                kg (As per Thai Guideline).

      All infants will receive ZDV for at least one week. Follow-up of women and infants is carried
      out on an outpatient basis except for delivery and the first three days after delivery.
      Mothers and infants are followed-up for 24 months after delivery.

      Note: The study was stopped and data unblinded upon DSMB recommendations in September 2010
      because of changes in Thai PMTCT guidelines recommending use of HAART in all HIV infected
      pregnant women regardless of their CD4 count. At the time of unblinding 435 pregnant women
      had been enrolled and follow-up of these women and their children is continuing.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in National PMTCT guidelines in Thailand
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Definitive HIV infection in infants as assessed by positive HIV DNA PCR on two peripheral blood samples</measure>
    <time_frame>At birth, 7-10 days, 1, 2, 4 and 6 months of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety for mothers and children of two NVP doses in neonates with and without maternal single dose NVP at onset of labor or LPV/r from 28 weeks gestation.</measure>
    <time_frame>From randomization during pregnancy until 24 months after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">435</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP-NVP:
In women, one NVP 200 mg tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PL-NVP:
In women, one placebo tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LPV/r:
In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maternal and infant nevirapine</intervention_name>
    <description>In women, one NVP 200 mg tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maternal placebo and infant nevirapine</intervention_name>
    <description>In women, one placebo tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours
Comparison between Arms 1 and 2 is double-blinded.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maternal lopinavir+ritonavir</intervention_name>
    <description>- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine</intervention_name>
    <description>In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-Entry Criteria

          -  Evidence of HIV infection (documented by two HIV antibody tests on two different
             dates)

          -  Intend to be followed at a study site for the duration of the study

          -  At least 18 years old

          -  Written informed consent.

        Inclusion Criteria:

        Women are eligible for the study if they

          -  met all pre-entry criteria

          -  Evidence of HIV infection, as documented by two serology tests obtained at two
             different dates;

          -  between 28 and 36 weeks gestational age;

          -  antiretroviral naïve except for exposure to ZDV prophylaxis PMTCT;

          -  CD4 count above 250 cells/mm3 (within 4 months prior to randomization)

          -  agreement not to breastfeed;

          -  consent to participate and to be followed for the duration of the study;

          -  and the following laboratory values within 14 days prior to randomization:

          -  hemoglobin &gt; 8.5 mg/dl;

          -  absolute neutrophil count &gt; 750 cells/mm3;

          -  platelets &gt; 50,000 cells/mm3;

          -  SGPT ≤ 5 times upper limit of normal;

          -  serum creatinine ≤ 1.5 times upper limit of normal (women with a serum creatinine &gt;
             1.5 times upper limit of normal must have a measured eight-hour urine creatinine
             clearance &gt; 70 ml/min).

        Exclusion criteria:

          -  Evidence of pre-existing fetal anomalies incompatible with life;

          -  patients who meet the criteria of Classes III/IV of the WHO classification of
             HIV-associated clinical disease;

          -  known hypersensitivity to any benzodiazepine;

          -  active tuberculosis;

          -  concurrent participation to any other clinical trial;

          -  receipt of benzodiazepines or antiretroviral agent other than ZDV;

          -  uncontrolled hypertension;

          -  anticoagulant therapy or magnesium sulfate within 2 weeks of enrollment or the need
             for them during labor or at delivery.

        If any of these conditions occurs after randomization, the women will be excluded from
        study drug dosing. Women with CD4 count lower than 250 cells/mm3 will be excluded from the
        study and offered HAART in the context of the national program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Lallemant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nopparat Rajathanee Hospital</name>
      <address>
        <city>Kannayao</city>
        <state>Bangkok</state>
        <zip>10230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Saimai</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chachoengsao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chachoengsao</state>
        <zip>24000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chantaburi</state>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Mae Rim</city>
        <state>Chiang Mai</state>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanpatong Hospital</name>
      <address>
        <city>Sanpatong</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Mae Chan</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Sai Hospital</name>
      <address>
        <city>Mae Sai</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Hospital</name>
      <address>
        <city>Phan</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Saen Hospital</name>
      <address>
        <city>Chiang Saen</city>
        <state>Chiangrai</state>
        <zip>57150</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chiangrai</state>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiangpapao Hospital</name>
      <address>
        <city>Wiangpapao</city>
        <state>Chiangrai</state>
        <zip>57170</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banglamung Hospital</name>
      <address>
        <city>Banglamung</city>
        <state>Chonburi</state>
        <zip>20150</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chonburi</state>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panasnikom Hospital</name>
      <address>
        <city>Panasnikom</city>
        <state>Chonburi</state>
        <zip>20140</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Udom Hospital</name>
      <address>
        <city>Sri Racha</city>
        <state>Chonburi</state>
        <zip>20230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalasin Hospital</name>
      <address>
        <city>Muang</city>
        <state>Kalasin</state>
        <zip>46000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phaholpolphayuhasena Hospital</name>
      <address>
        <city>Munag</city>
        <state>Kanjanaburi</state>
        <zip>71000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lampang Hospital</name>
      <address>
        <city>Muang, Lampang</city>
        <state>Lampang</state>
        <zip>52000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahasarakam Hospital</name>
      <address>
        <city>Muang</city>
        <state>Mahasarakam</state>
        <zip>44000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakhon Si Thammarat Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nakhon Si Thammarat</state>
        <zip>80000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakhonpathom Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nakhonpathom</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nong Khai Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nong Kai</state>
        <zip>43000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pranangklao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nonthaburi</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pathumthani Hospital</name>
      <address>
        <city>Muang</city>
        <state>Pathumthani</state>
        <zip>12000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Kham Hospital</name>
      <address>
        <city>Chiang Kham</city>
        <state>Phayao</state>
        <zip>56110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhachinaraj Hospital</name>
      <address>
        <city>Muang</city>
        <state>Pitsanulok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rayong Hospital</name>
      <address>
        <city>Muang</city>
        <state>Rayong</state>
        <zip>21000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutsakhon Hospital</name>
      <address>
        <city>Muang</city>
        <state>Samutsakhon</state>
        <zip>74000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songkhla Hospital</name>
      <address>
        <city>Muangsongkhla</city>
        <state>Songkhla</state>
        <zip>90100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hat Yai Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trat Hospital</name>
      <address>
        <city>Muang</city>
        <state>Trat</state>
        <zip>23000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Hospital Regional Center I</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Center Region 10,</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fang Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chomthong Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50160</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somdej Pranangchao Sirikit Hospital</name>
      <address>
        <city>Chonburi</city>
        <zip>20180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Promotion Centre 6,</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamphun Hospital</name>
      <address>
        <city>Lamphun</city>
        <zip>51000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao Provincial Hospital</name>
      <address>
        <city>Phayao</city>
        <zip>56000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vachira Phuket Hospital</name>
      <address>
        <city>Phuket</city>
        <zip>83000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutprakarn Hospital</name>
      <address>
        <city>Samutprakarn</city>
        <zip>10280</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.phpt.org</url>
    <description>Program for HIV Prevention and Treatment (Thailand)</description>
  </link>
  <reference>
    <citation>Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, McIntosh K, Thaineua V; Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004 Jul 15;351(3):217-28. Epub 2004 Jul 9.</citation>
    <PMID>15247338</PMID>
  </reference>
  <reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.</citation>
    <PMID>15247339</PMID>
  </reference>
  <reference>
    <citation>Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S, Novitsky V, Makhema J, Lagakos S, Essex M. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006 Jun 12;20(9):1281-8.</citation>
    <PMID>16816557</PMID>
  </reference>
  <results_reference>
    <citation>Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.</citation>
    <PMID>20625263</PMID>
  </results_reference>
  <results_reference>
    <citation>Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators. Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.</citation>
    <PMID>26372485</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>Marc Lallemant</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>Thailand</keyword>
  <keyword>Developing Countries</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Mother-to-child transmission</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

